Intellia Therapeutics, Inc. (NTLA)
| Market Cap | 1.82B +61.1% |
| Revenue (ttm) | 59.51M +12.6% |
| Net Income | -399.98M |
| EPS | -3.34 |
| Shares Out | 140.13M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,205,060 |
| Open | 13.38 |
| Previous Close | 13.51 |
| Day's Range | 13.08 - 13.50 |
| 52-Week Range | 7.95 - 28.25 |
| Beta | 1.79 |
| Analysts | Buy |
| Price Target | 23.94 (+84.37%) |
| Earnings Date | Aug 6, 2026 |
About NTLA
Intellia Therapeutics, Inc. operates as a clinical-stage genome editing company focused on developing potentially curative therapeutics using CRISPR/Cas9-based technologies. The company offers clustered, regularly interspaced short palindromic repeats (“CRISPR”)/CRISPR associated 9 (“Cas9”) technology for genome editing. The company provides a modular platform, to advance in vivo and ex vivo therapies for diseases. The company’s in vivo product candidates include nexiguran ziclumeran, or NTLA-2001 for the treatment of transthyretin amyloidosis;... [Read more]
Financial Performance
In 2025, Intellia Therapeutics's revenue was $67.67 million, an increase of 16.92% compared to the previous year's $57.88 million. Losses were -$412.69 million, -20.49% less than in 2024.
Financial StatementsAnalyst Summary
According to 19 analysts, the average rating for NTLA stock is "Buy." The 12-month stock price target is $23.94, which is an increase of 84.37% from the latest price.
News
Cathie Wood’s ARK Investment buys 169K shares of Intellia Therapeutics today
20:17 EDT Cathie Wood’s ARK Investment buys 169K shares of Intellia Therapeutics (NTLA) today
Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass., Aug. 07, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing a...
Intellia Therapeutics upgraded to Outperform from In Line at Evercore ISI
As previously reported, Evercore ISI analyst Jonathan Miller upgraded Intellia Therapeutics (NTLA) to Outperform from In Line with a price target of $24, up from $16, after the company “finally…
Intellia Therapeutics upgraded to Outperform from In Line at Evercore ISI
Evercore ISI upgraded Intellia Therapeutics (NTLA) to Outperform from In Line with a price target of $24, up from $16.
Intellia Therapeutics Earnings Call Transcript: Q2 2026
Major clinical progress was achieved in phase III programs for HAE and ATTR, with positive efficacy and safety data, a rolling BLA submission for lonvo-z, and resumed nex-z trials. Financially, cash reserves increased to $628.4 million, supporting operations into 2028.
Intellia Therapeutics Earnings release: Q2 2026
Intellia Therapeutics released its Q2 2026 earnings on August 6, 2026, summarizing the period's financial results.
Intellia Therapeutics Quarterly report: Q2 2026
Intellia Therapeutics has published its Q2 2026 quarterly earnings report on August 6, 2026.
Intellia Therapeutics reports Q2 EPS (80c), consensus (78c)
Reports Q2 revenue $7.66M, consensus $12.98M. “The second quarter was a momentous period for Intellia highlighted by the positive Phase 3 HAELO clinical trial results we reported for lonvo-z in…
Intellia Therapeutics Announces Second Quarter 2026 Financial Results and Business Updates
CAMBRIDGE, Mass., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing a...
Intellia Therapeutics to Hold Conference Call on August 6 to Discuss Second Quarter 2026 Financial Results and Business Updates
CAMBRIDGE, Mass., July 30, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing a...
Intellia Therapeutics downgraded to Underperform from Peer Perform at Wolfe Research
Wolfe Research analyst Andy Chen downgraded Intellia Therapeutics (NTLA) to Underperform from Peer Perform with a $9 price target The firm said its primary concern is cash constraint, adding that…
Intellia Therapeutics price target raised to $17 from $12 at Wedbush
Wedbush raised the firm’s price target on Intellia Therapeutics to $17 from $12 and keeps a Neutral rating on the shares. Relevant to Intellia Therapeutics (NTLA), AstraZeneca (AZN) and Ionis…
Intellia Therapeutics rises 12.9%
Intellia Therapeutics (NTLA) is up 12.9%, or $1.88 to $16.43.
Intellia Therapeutics rises 10.7%
Intellia Therapeutics (NTLA) is up 10.7%, or $1.56 to $16.11.
Intellia Therapeutics presents additional results from Phase 3 HAELO trial
Intellia Therapeutics (NTLA) presented additional positive results from the global Phase 3 HAELO clinical trial of lonvo-z for hereditary angioedema, HAE, in a late-breaking oral presentation at the E...
Intellia Therapeutics Reports Additional Positive Phase 3 Results for Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema
CAMBRIDGE, Mass., June 13, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing a...
Intellia Therapeutics Transcript: AGM 2026
The meeting covered board introductions, voting on director elections, auditor ratification, and executive compensation, with all proposals approved. No questions were raised by stockholders during the session.
Intellia Therapeutics Transcript: Jefferies Global Healthcare Conference 2026
Phase III data show a single infusion yields 87% attack reduction and eliminates long-term prophylaxis in HAE, with a strong safety profile and broad patient benefit. Rolling BLA submission is underway, targeting a 2027 U.S. launch, while commercialization and education efforts ramp up.
Intellia Therapeutics to Report Additional Phase 3 HAELO Data for Lonvoguran Ziclumeran (lonvo-z) in Late-Breaking Oral Presentation at EAACI 2026
CAMBRIDGE, Mass., June 01, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing a...
Intellia Therapeutics Transcript: RBC Capital Markets Global Healthcare Conference 2026
Significant progress was highlighted, including completion of the first phase III in vivo CRISPR trial and strong HAE data showing most patients free of disease after one treatment. Rolling BLA submissions are underway, and TTR programs are advancing with new safety protocols and global enrollment.
Intellia Therapeutics price target raised to $17 from $13 at Bernstein
Bernstein raised the firm’s price target on Intellia Therapeutics (NTLA) to $17 from $13 and keeps a Market Perform rating on the shares. Biotech has had a strong start to…
Intellia Therapeutics price target lowered to $25 from $30 at H.C. Wainwright
H.C. Wainwright lowered the firm’s price target on Intellia Therapeutics (NTLA) to $25 from $30 and keeps a Buy rating on the shares. The firm cites dilution from the recent…
Intellia Therapeutics Transcript: Bank of America Global Healthcare Conference 2026
Phase III HAELO study showed 87% attack rate reduction and 62% of patients attack and therapy free, with commercialization of lonvo-z targeted for next year. TTR program is progressing post-clinical hold, and strong payer interest supports a premium pricing strategy.
Intellia Therapeutics price target lowered to $19 from $20 at BofA
BofA lowered the firm’s price target on Intellia Therapeutics (NTLA) to $19 from $20 and keeps a Neutral rating on the shares. The firm updated operating expense trends and share…
Intellia Therapeutics price target lowered to $49 from $58 at Canaccord
Canaccord lowered the firm’s price target on Intellia Therapeutics (NTLA) to $49 from $58 and keeps a Buy rating on the shares. The firm said its 1Q26 report was largely…